• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Valeant's $31 Billion Debt Could Be Fatal to Shareholders

Investors who think they spot a discount in the drugmaker's shares need to first look at its precarious debt situation.
By JAMES PASSERI Mar 16, 2016 | 11:15 AM EDT
Stocks quotes in this article: VRX

Investors may think they can now spot a discount in Valeant Pharmaceuticals' (VRX) share price, after more than half of the troubled drugmaker's market cap was erased in a massive selloff Tuesday.

But they need to first look at the company's precarious debt problems before jumping in.

As Real Money reported, bleak revisions to Valeant's already dismal 2016 outlook Tuesday seemed to be more than even the most risk-prone could handle -- the last straw atop stagnant growth challenges: a congressional probe into its pricing policies, a Securities and Exchange Commission investigation into its revenue bookkeeping, and a political firestorm over "predatory pricing" alleged by Democratic presidential front-runner Hillary Clinton.

After all, the company is saddled with about $31 billion in debt, primarily comprising tranches of unsecured bonds that lately have been tanking in secondary markets. And the shareholders should keep an eye on the quickly worsening situation, because at worst it could translate into a complete equity wipe-out. 

This is especially true if Valeant's postponed annual 10-K filing with the SEC is further delayed, which means Valeant may violate its bond covenants, and that could even result in technical defaults if not resolved, further putting the screws to the shareholders, who have a vested stake in the drugmaker's overall solvency.

"With all of the debt on ... the balance sheet and the timing of the 10k filing still not certain, we do not believe an 'all clear' signal is warranted," BTIG Research analyst Timothy Chiang said in a Tuesday report. "Little visibility was provided on what assets might be divested. We remain on the sidelines and will continue to watch how the Board reacts to what has occurred today."

The burden of Valeant's debt is most clearly visible in its more than $1.5 billion in annual interest expenses, which has exacerbated shareholder concerns over the drugmaker's rising costs of good sold. For instance Valeant's $737 million in such costs in the fourth quarter are up 25% year over year.

And to get a sense of Valeant's timeframe in its effort to pay down debt, its nearest bond maturity is a $1.6 billion senior unsecured tranche due in August 2018.

Because this debt component -- rated B2 by Moody's and B- by Standard & Poor's -- will be repaid sooner than the rest of Valeant's bonds, they are performing comparatively well in secondary markets at $0.91 on the dollar. 

But even these bonds are still in free-fall, trading down more than 7% since Friday, though they appear bulletproof compared to Valeant's other debt components. For example, Valeant's $1.5 billion tranche of senior unsecured notes due 2023 are trading down at $70.91 on the dollar as of Wednesday morning, and have fallen 15% since Friday. 

This is a clear indication that -- like shareholders who could be wiped out in a restructuring -- lenders are beginning to fear insolvency is on Valeant's horizon, although lenders are better protected with a stake higher in the firm's capuital structure.

Surely, if lenders continue to balk at Valeant's paper, the financing woes will be heaped onto shareholders as maturities approach, with little to no hope of reasonable refinancing means.

Real Money readers seem to be wary as well. As of Tuesday morning, 41% of the 205 respondents to Real Money's Twitter poll said they see Valeant's stock, which opened at $32.90 Wednesday, falling at least as low as $10, while 29% forecast $20 lows.

Valeant: How low can it go? Read and vote! https://t.co/cfe2o3Hzh5

¿ RealMoney (@TSTRealMoney) March 15, 2016

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Technology

More from Healthcare

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login